Background: Mortality studies in multiple sclerosis (MS) are valuable to identify changing disease patterns and inform clinical management. This study examines mortality in a British MS cohort. Methods: Patients were selected from the southeast Wales MS registry. Hazard of death was analysed using Cox proportional hazards regression, adjusted for onset age, annualised relapse rate, initial disease course, time to EDSS 4.0, sex, socioeconomic status, and onset year. Age-and sex-stratified standardised mortality ratios (SMRs) were calculated by EDSS scores. Results: Median time from MS diagnosis to death was 35.5 years and median age 73.9. Older onset age (hazard ratio [HR] 1.05, 95% confidence interval 1.03-1.06) was associated with increased hazard of death. Primary progressive course was associated with increased hazard of death in women (HR 2.04, 1.15-3.63) but not men (HR 1.23, 0.61-2.47) . Slow time to EDSS 4.0 (HR 0.41, 0.28-0.60) and high socioeconomic status (HR 0.54, 0.37-0.79) were associated with reduced hazard of death. SMR increased from EDSS 6.0 (3.86, 2.63-5.47) but more substantially at EDSS 8.0 (22.17, 18.20-26.75).
Introduction
Disease-specific mortality data remains a core epidemiological resource. Death is a universal and recognizable outcome, and mortality data therefore has value in informing clinical management, deriving case fatality, and identifying changing patterns of disease frequency. It is also an essential component in health economic modelling in chronic diseases such as multiple sclerosis (MS). High quality mortality data can be used to compare effects of new treatments on overall burden of disease, which can then be translated into estimates of long-term treatment efficacy and qualityadjusted life years (QALYs). 1 Over the last decade this has become particularly significant for MS as multiple new disease-modifying therapies (DMT) have become available.
Mortality studies in MS have commonly focused on analysis of cause of death. [2] [3] [4] [5] [6] [7] [8] Among those studies that have examined mortality in more detail, MS has consistently been observed to be associated with a higher risk of death, [9] [10] [11] [12] [13] [14] [15] with this effect most apparent for younger patients 13 and those with primary progressive disease. 11, 14 However, few studies have linked mortality statistics to detailed prospective clinical data from disease onset, and where mortality has been reported as part of a prospective study, data have largely been derived from MS populations where deaths all occurred in the twentieth century, 16 lessening relevance to current clinical practice. This has also been compounded by a general trend of improvement in life expectancy in successive decades as a result of advances in public health and nutrition together with improvements in medical management and survival from common conditions, particularly cardiovascular disease. 17 For these reasons it is important to employ contemporary mortality statistics for comparator data where possible in order to ensure that any observed differences in disease specific survival are not attributable to confounding factors.
In this study we examine a contemporary cohort of British MS patients, with a particular focus on clinical variables associated with risk of death. In addition we have explored the relationship between disability level and standardised mortality ratios (SMR), as well as providing descriptors of cause of death according to death certificate data.
Methods

Patient selection
The MS registry of southeast Wales was first established in a prevalence study in 1985, 18 and since 1999 longitudinal data has been collected prospectively on all patients seen in the neuroinflammatory clinics at the University Hospital of Wales (a tertiary referral centre) and the Royal Gwent Hospital, which serve the cities of Cardiff and Newport and the surrounding areas; a population of 1.4 million. The registry has been estimated to include over 97% of MS patients in the region. 19 Patients are recruited at time of first presentation to the clinics, when demographic data and details of onset event, including degree of recovery, are collected. At all encounters (recruitment and follow-up) data is collected on current disease course, relapses since last encounter, disability (measured using the Expanded Disability Status Scale 20 (EDSS)), and disease modifying therapy (DMT) and its effects. Socioeconomic status was classified using the Welsh Index of Multiple Deprivation (WIMD), 21 which is the Welsh Government's official measure of deprivation in Wales and is based on residential postcode. For this analysis, socioeconomic status quartiles were used. Data is stored securely in a custom-built database on National Health Service (NHS) servers. Written consent is obtained from all patients. This study was approved by the South East Wales Research Ethics Committee (ref no.05/WSE03/111).
In 1985 the 379 patients of the original prevalence study [18] were registered with the Office of Population Censuses and Surveys, which allowed direct notification to the research team whenever a new death occurred in this patient group. Results from an interim analysis have already been reported, 22 and notification of deaths from this pilot cohort remains ongoing. For the remainder of the registry patients recruited since 1985, death was confirmed via several converging pathways.
The disease registry is linked to NHS records, enabling automatic upload of any hospital record of death. Deaths are also notified during a weekly clinical meeting by specialist staff embedded in community and hospital care. Finally in order to confirm date of death and to identify any deaths not detected using the first two methods, data was cross-referenced with the Welsh Demographic Service (http://www.publichealthwalesobservatory.wales.nhs.uk/wds), which is government data from Public Health Wales providing demographic data on all residents of Wales who are registered with a general practitioner.
Death certificate data collection
Copies of death certificates were requested from the General Register Office (https://www.gro.gov.uk). Death certificates in the UK are structured according to international guidelines from the World Health Organisation, 23 Standard statistical methods were used to derive sex-and age-stratified standardised mortality ratios (SMRs) 25 by EDSS score as follows. EDSS scores were banded into <4.0, 4.0-5.5, 6.0-6.5, 7.0-7.5, 8.0-8.5, and 9.0-9.5. Next, sex and age group (under 30, 30-44, 45-59, 60-74, 75-89, ≥90 years) of patients in each EDSS band was tabulated using the whole cohort, to produce an age profile for each EDSS band for males and females separately. Expected deaths for each EDSS band were then calculated based on the age and sex profile for each band, using sex-and age-stratified comparative data for the population of southeast Wales. 26 Observed number of deaths in each EDSS band were counted, with EDSS score at death taken to be the EDSS score recorded nearest death (and not more than five years before death). The ratio between the observed and expected number of deaths was calculated (to provide the SMR) and tested using χ 2 test. SMR was not calculated for EDSS scores <4 to avoid immortal time bias, and because the number of patients dying at low EDSS scores was too small to allow reliable calculation.
Results
Demographics
A total of 2604 patients was identified (1851 recruited since the original prevalance study in 1985 18 ), with a total of 45379 patient-years of follow-up and a median of 19.3 years follow-up per patient. Of these, 579 (22.2%) were deceased, and 79.3% of these had died in the last twenty years.
Thirty-one (5.4%) deceased patients had received DMT: two alemtuzumab, four mitoxantrone, and the remainder either interferon-1β or glatiramer acetate. Patient demographics are summarised in Table 1 . were all associated with a longer time from MS diagnosis to death. Female sex and higher socioeconomic status were also associated with an older age at death. However, a younger age at onset and a relapsing initial disease course were associated with a younger age at death (Figure 1 , Table 2 ). (Table 3 ). When analysed separately by sex, the only way in which findings differed from the main analysis was that primary progressive disease course was associated with increased hazard of death in women (HR 2.04, 95% CI 1.15-3.63) but not in men (HR 1.23, 95% CI 0.61-2.47, Table   3 ). None of the models violated the proportional hazards assumptions. EDSS score before death was ≤4.0 in four patients, and these were not included in the next steps of analysis. At EDSS scores of 6 or greater SMR was increased, most substantially at EDSS scores of 8 or greater (Table 4 ). 
Discussion
In this study we have presented a comprehensive analysis of mortality in a contemporary British MS population, with a median age at death of 73.9 years, and median time from MS diagnosis to death of 35.5 years. We found that older age at MS diagnosis, primary progressive disease course, rapid time to EDSS 4.0, and low socioeconomic status were associated with increased hazard of death. Additionally, clinical variables associated with hazard of death were similar for men and women, with the exception of primary progressive disease course which was associated with an increased hazard of death for women only. We have also described standardised mortality ratios (SMR) by EDSS score, and shown that SMR increases with EDSS, most substantially when EDSS is ≥8.0.
Current life expectancy in Wales is 78.5 years for men and 82.3 years for women, 27 implying that MS is associated with a shortened lifespan relative to the general population. However, a valuable aspect of our study is the direct comparison with historical data from the 1985 prevalent cohort in the same region, 22 28 so the improvement in survival for MS patients has been greater than that for the general population. Other studies have found a similar improvement, particularly in northern European cohorts, 8, 9, 13, 15, 29 which may reflect better symptomatic care over recent years and emphasises the value of contemporary data for current and future analyses which incorporate survival data. Not all studies have found improving life expectancy: no evidence was found for a change in survival over time in the British Columbia cohort in Canada. 11 In addition, a recent metaanalysis of SMRs reported between 1949 and 2012 found no evidence for an improvement in mortality ratios. 30 However, this meta-analysis was based on multiple cohorts each measured at a single point in time, rather than repeated observations in the same cohort over a period of years. It is possible that variation in life expectancy between different populations may mask the effect of improvements in life expectancy in individual cohorts over time within a single population.
Although women have both longer survival times 10, 14, 31 and are older at death than men, 11 adjustments to compare with the general population reveal that relative mortality is worse for women, 10, 13 which may be most significant for women with PPMS compared to R-MS. 11 We also observed a difference in survival by sex and disease course: in our cohort PPMS was associated with increased hazard of death in women, but not in men. In addition, those with PPMS were older at death than those with relapsing onset MS, an effect which is largely explained by the older age at onset in PPMS patients (45 years versus 31 years), since other clinical variables within PPMS and relapsing-onset MS were either similar, or would be expected to have the opposite effect (i.e. PPMS is more common in men, who generally would be expected to have a shorter life expectancy).
Differences in survival for sub-groups of MS patients are important as they may represent a group where targeted intervention may have most effect, and with the growing recent interest in potential DMTs in progressive disease, this is particularly relevant.
To our knowledge, this is the most detailed examination of risk of death by EDSS score, although in general risk of death has been observed to increase with higher levels of disability 32, 33 Our finding is consistent with observations of a divergence in survival after 20 years of MS, 13 which is the point at which significant disability commonly accumulates 34 The strength of this study is its basis in a large population-based cohort, with prospectively collected data on 70% of patients from onset of disease. This has allowed us to explore survival in detail, as well as SMRs by EDSS score. We were able to trace over 97% of death certificates, which reflects the high quality of the data and degree of follow-up. Another strength was the ability to directly compare mortality to that reports from MS patients prevalent in 1985, 22 providing valuable insights into the changing life expectancy for MS patients, and illustrates the value of analysing contemporary datasets.
In conclusion, we have shown an improvement in the life expectancy of patients in south east Wales since 1985 in a largely DMT-naive population. We have demonstrated that SMR increases substantially above EDSS 7.5, which will have implications for health economic modelling as new DMTs are developed, and for clinical practice regarding end-of-life care in patients with high EDSS scores. These data serve to illustrate that mortality studies remain relevant and important for understanding disease progression, long-term prognosis, and the effects of new interventions.
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